NCT04001725
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Must have radiologically documented (contrast-enhanced CT or MRI) diagnosis of measurable brain metastases within past 28 days
Exclusions: Patients with leptomeningeal carcinomatosis or a history of brain metastases
https://ClinicalTrials.gov/show/NCT04001725